Related Experiment Video
Updated: Feb 4, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Epigenetic Metal-Organic Framework Nanoagonist Overcomes Triple Defenses to Enable Effective
Ling Lin1,2, Qiaoling Zhang1,2, Xue Liu1
1Department of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, P. R. China.
Abstract:
Platinum-resistant ovarian cancer (PROC) responds poorly to platinum chemotherapy and evades immune surveillance by suppressing the cGAS-STING pathway, leading to poor outcomes. Herein, we developed an epigenetic metal-organic framework (MOF) nanoagonist (CMZ-Pt-SA@HA) that overcomes cisplatin (CisPt) resistance while restoring immune activation. The platform consists of Mn-ZIF-8 encapsulating CaO2 and co-loaded with CisPt and SAHA (a histone deacetylase inhibitor), then modified with hyaluronic acid to enable tumor targeting and controlled release. CMZ-Pt-SA@HA is multifunctional: SAHA downregulates resistance proteins epigenetically, CaO2 triggers calcium overload and oxygen release, and Mn2+/Zn2+ enhances oxidative stress and STING signaling, collectively strengthening chemo-metalloimmunotherapy. These mechanisms intensify CisPt-induced DNA damage and stimulate immune activation. CMZ-Pt-SA@HA applies a three-step "POP" strategy to overcome PROC's triple defenses: (I) Pre-targeting to enhance DNA-CisPt adducts; (II) On-targeting to block DNA repair; and (III) Post-targeting to induce apoptosis by relieving hypoxia, arresting the cell cycle, damaging mitochondria, and activating cGAS-STING. Whether used alone in subcutaneous tumors in preclinical ID8 and patient-derived xenograft mouse models, or combined with anti-PD-L1 therapy in ascites metastasis models, CMZ-Pt-SA@HA consistently showed strong therapeutic efficacy. Its Mn2+-based magnetic resonance imaging (MRI) capability further supports image-guided therapy and clinical translation.
Insights
A novel nanoagonist overcomes platinum-resistant ovarian cancer by restoring immune activation and enhancing chemotherapy. This epigenetic metal-organic framework (MOF) nanoagonist shows strong therapeutic efficacy in preclinical models.
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Cancer Therapy
Background:
- Platinum-resistant ovarian cancer (PROC) exhibits poor response to chemotherapy and immune evasion via cGAS-STING pathway suppression.
- Developing novel strategies is crucial to overcome resistance and restore anti-tumor immunity in PROC.
Purpose of the Study:
- To develop a multifunctional metal-organic framework (MOF) nanoagonist (CMZ-Pt-SA@HA) that overcomes cisplatin resistance and reactivates the immune system in PROC.
- To investigate the therapeutic efficacy and underlying mechanisms of CMZ-Pt-SA@HA in preclinical PROC models.
Main Methods:
- Fabrication of CMZ-Pt-SA@HA: Mn-ZIF-8 MOF encapsulating CaO2, co-loaded with cisplatin (CisPt) and SAHA, modified with hyaluronic acid for tumor targeting.
- Evaluation of CMZ-Pt-SA@HA's multi-pronged attack: epigenetic modification, calcium overload, oxygen release, oxidative stress, and STING pathway activation.
- Assessment of therapeutic efficacy in subcutaneous and metastatic preclinical PROC models (ID8 and patient-derived xenografts), alone and in combination with anti-PD-L1 therapy.
- Utilizing Mn2+-based MRI for image-guided therapy.
Main Results:
- CMZ-Pt-SA@HA effectively downregulates resistance proteins, enhances CisPt-induced DNA damage, and stimulates immune activation by targeting the cGAS-STING pathway.
- The nanoagonist demonstrated strong therapeutic efficacy in reducing tumor burden and improving outcomes in various preclinical PROC models.
- Combination therapy with anti-PD-L1 showed enhanced efficacy in ascites metastasis models.
- MRI capability facilitated image-guided treatment assessment.
Conclusions:
- CMZ-Pt-SA@HA represents a promising chemo-metalloimmunotherapy strategy for overcoming platinum resistance in ovarian cancer.
- The multifunctional nanoagonist restores immune surveillance and exhibits significant therapeutic potential for PROC.
- The developed platform offers a translatable approach for image-guided cancer therapy.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Treatment Resistant Cancers
Organic Compounds
Properties of Transition Metals
Bonding in Metals

